TY - JOUR
T1 - Metabolic and metagenomic outcomes from early-life pulsed antibiotic treatment
AU - Nobel, Yael R.
AU - Cox, Laura M.
AU - Kirigin, Francis F.
AU - Bokulich, Nicholas A.
AU - Yamanishi, Shingo
AU - Teitler, Isabel
AU - Chung, Jennifer
AU - Sohn, Jiho
AU - Barber, Cecily M.
AU - Goldfarb, David S.
AU - Raju, Kartik
AU - Abubucker, Sahar
AU - Zhou, Yanjiao
AU - Ruiz, Victoria E.
AU - Li, Huilin
AU - Mitreva, Makedonka
AU - Alekseyenko, Alexander V.
AU - Weinstock, George M.
AU - Sodergren, Erica
AU - Blaser, Martin J.
N1 - Funding Information:
Supported in part by R01-DK090989, 1UL1RR029893, U54HG004968 from the NIH, by the Knapp Family Fund, Ziff Fund, Diane Belfer Program for Human Microbial Ecology, and by the C & D Fund. We thank the Microbial Genomics Group at The Genome Institute at Washington University School of Medicine for production and analysis support. We thank Hao Chen, PhD for help with data deposition. This work has utilized computing resources at the High Performance Computing Facility of the Center for Health Informatics and Bioinformatics at the NYU Langone Medical Center.
Publisher Copyright:
© 2015 Macmillan Publishers Limited. All rights reserved.
PY - 2015/6/30
Y1 - 2015/6/30
N2 - Mammalian species have co-evolved with intestinal microbial communities that can shape development and adapt to environmental changes, including antibiotic perturbation or nutrient flux. In humans, especially children, microbiota disruption is common, yet the dynamic microbiome recovery from early-life antibiotics is still uncharacterized. Here we use a mouse model mimicking paediatric antibiotic use and find that therapeutic-dose pulsed antibiotic treatment (PAT) with a beta-lactam or macrolide alters both host and microbiota development. Early-life PAT accelerates total mass and bone growth, and causes progressive changes in gut microbiome diversity, population structure and metagenomic content, with microbiome effects dependent on the number of courses and class of antibiotic. Whereas control microbiota rapidly adapts to a change in diet, PAT slows the ecological progression, with delays lasting several months with previous macrolide exposure. This study identifies key markers of disturbance and recovery, which may help provide therapeutic targets for microbiota restoration following antibiotic treatment.
AB - Mammalian species have co-evolved with intestinal microbial communities that can shape development and adapt to environmental changes, including antibiotic perturbation or nutrient flux. In humans, especially children, microbiota disruption is common, yet the dynamic microbiome recovery from early-life antibiotics is still uncharacterized. Here we use a mouse model mimicking paediatric antibiotic use and find that therapeutic-dose pulsed antibiotic treatment (PAT) with a beta-lactam or macrolide alters both host and microbiota development. Early-life PAT accelerates total mass and bone growth, and causes progressive changes in gut microbiome diversity, population structure and metagenomic content, with microbiome effects dependent on the number of courses and class of antibiotic. Whereas control microbiota rapidly adapts to a change in diet, PAT slows the ecological progression, with delays lasting several months with previous macrolide exposure. This study identifies key markers of disturbance and recovery, which may help provide therapeutic targets for microbiota restoration following antibiotic treatment.
UR - http://www.scopus.com/inward/record.url?scp=84934775028&partnerID=8YFLogxK
U2 - 10.1038/ncomms8486
DO - 10.1038/ncomms8486
M3 - Article
C2 - 26123276
AN - SCOPUS:84934775028
SN - 2041-1723
VL - 6
JO - Nature communications
JF - Nature communications
M1 - 7486
ER -